Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2020-01-09
Target enrollment:
Participant gender:
Summary
This Phase II trial is being developed following the completion of a Phase I study of the
combination of temsirolimus and sorafenib in 25 first-line therapy patients with advanced
hepatocellular carcinoma (December 2009 through April 2012). The maximum tolerated dose (MTD)
and recommended phase II dose (RP2D) of the combination of temsirolimus is 10 mg IV weekly
plus sorafenib 200 mg (oral, twice daily).